DGAP-News: Biotest AG: Biotest increases guidance significanty
(firmenpresse) - DGAP-News: Biotest AG / Key word(s): Quarter Results
Biotest AG: Biotest increases guidance significanty
12.11.2013 / 09:15
---------------------------------------------------------------------
/
PRESS RELEASE
Biotest increases guidance significanty
- Increase of earnings before tax (EBT) by 41.2%
- EBIT increase by 21.6%
- Successful placement of a privately placed promissory note
(Schuldschein) of EUR 210 million equivalent in the capital market
Dreieich, November 12, 2013. The Biotest Group increased sales by 13.1 % in
the first nine months of 2013 compared to the same period in the previous
year. In the reporting period the Group generated revenues of EUR 367.5
million compared to EUR 324.9 million in the previous year.
The Biotest Group generated revenue in the amount of USD 25 million with
Bivigam(R), an immunoglobulin developed and marketed in the USA which is
used to treat patients with primary humoral immune deficiencies.
Operating profit (EBIT) increased substantially by 21.6 % in the first nine
months of 2013 compared to the same period in the previous year. The
Biotest Group recorded EBIT of EUR 39.9 million in the period between
January and September 2013 compared to EUR 32.8 million in the comparable
period in 2012, which was accompanied by an increase in the EBIT margin
from 10.1 % to 10.9 %. This increase was attributable to the segments
Therapy and Plasma&Services. EBIT of the Therapy segment increased
significantly by 21.6 % from EUR 20.4 million to EUR 24.8 million.
The financial result improved considerably in the first nine months of 2013
and amounted to EUR -3.9 million compared to EUR -7.3 million in the same
period in the previous year. The writedowns recognised as part of the final
sales of the Greek government bonds resulted in additional charges in 2012.
This resulted in earnings before taxes (EBT) of EUR 36.0 million for the
Biotest Group. EBT is therefore 41.2 % above the comparable amount of EUR
25.5 million for the same period in the previous year. Earnings after taxes
(EAT) increased significantly by 53.8 % from EUR 15.6 million to EUR 24.0
million. Altogether this resulted in earnings per share of EUR 1.96. This
is equivalent to an increase of 47.4 % compared to earnings per share of
EUR 1.33 for the previous year.
After the end of the reporting period, Biotest AG has successfully placed a
privately placed promissory note (Schuldschein) of EUR 210 million
equivalent in the capital market. Biotest offered five and seven year
tranches in Euro both on fixed and floating rate basis as well as ten year
tranches with a fixed interest rate. Furthermore, investors could subscribe
five-year US dollarfloating rate tranches. The funds raised from the
privately placedpromissory note (Schuldschein) will be used for the
expansion of theDreieich site as well as for general corporate financing.
In view of the high growth of plasma proteins Biotest decided to expand
production capacity as part of the 'Biotest Next Level' investment
programme. The aim of the project is to double production capacity at the
Dreieich location by 2018/19 and to further strengthen the international
competitiveness of the Company but also to contribute to achieving the
target sales figure in the amount of EUR 1 billion by the year 2020.
Outlook:
The business performance of the Biotest Group continues to be very
positive. This is also confirmed by the figures for thefirst nine months
of 2013. For this reason, the Board increases its EBIT forecast for the
2013 financial year from a so far expected increase of 10 % to 15 % to a 15
% to 20 % increase over the previous year. The Management Board reaffirms
its target of increasing sales by 10 % to 15 % in the financial year 2013.
The nine-month report is available on the company's website
http://www.biotest.de/ww/en/pub/investor_relations/publications/quarterly_
reports.cfm.The presentation for today's conference for analysts and
journalists as well as an audio file is available for download from the
website.
Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments.
The forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.
About Biotest
Biotest is a provider of plasma proteins and biotherapeutic drugs. With a
value added chain that extends from pre-clinical and clinical development
to worldwide sales, Biotest has specialised primarily in the areas of
clinical immunology, haematology and intensive medicine. Biotest develops
and markets immunoglobulins, coagulation factors and albumins based on
human blood plasma. These are used for diseases of the immune and
haematopoietic systems. In addition Biotest develops monoclonal antibodies
in the indications of rheumatoid arthritis and cancer of plasma cells,
which are produced by recombinant technologies. Biotest has about 1.900
employees worldwide. The preference shares of Biotest AG are listed in the
SDAX on the Frankfurt stock exchange.
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit
tel.: +49 (0) 6103 801-4406,
e-mail: investor_relations(at)biotest.de
fax: +49 (0) 6103 801-347
Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover,
München, Stuttgart
End of Corporate News
---------------------------------------------------------------------
12.11.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: investor_relations(at)biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
239224 12.11.2013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 12.11.2013 - 09:15 Uhr
Sprache: Deutsch
News-ID 315137
Anzahl Zeichen: 8685
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 321 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Biotest AG: Biotest increases guidance significanty"
steht unter der journalistisch-redaktionellen Verantwortung von
Biotest AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
